NVCT News
Archived Headlines
- US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs 02/04/22
- Micro-cap biotech Nuvectis Pharma prices IPO at $5, the low end of the downwardly revised range 02/04/22
- Oncology biotech Nuvectis Pharma slashes deal size by 58% ahead of $12 million IPO 01/18/22
- US IPO Week Ahead: December kicks off with a 1 IPO week 11/26/21
- Oncology biotech Nuvectis Pharma sets terms for $30 million IPO 10/28/21
See more
Biotech IPOs struggle to tread water amid challenging market conditions
Despite weak trading in the biotech sector, another drug developer is preparing to take on a challenging IPO market. Norovirus vaccine developer HilleVax (HLVX) plans to raise $175 million this week in the first major biotech IPO of the 2Q. ...read more
Sector-wide sell-off: IPOs from all but one sector have traded off in recent months
The IPO market set new records in 2021, but a recent sell-off has walloped new issuers across nearly every sector over the past 90 days and 30 days. The sole sector with positive average returns, energy has produced just two IPOs since 2021, one of which was...read more
Renaissance Capital's February IPO Market Update
In February, eight IPOs raised $271 million, a 76% y/y decline in IPO count and a 97% drop in proceeds. February IPOs raised fewer proceeds than any month since November 2018. The month’s issuers were primarily micro-caps, as the average deal size shrank...read more
All the small things: Small issuers keep the IPO market active as large deals wait
While market conditions have forced most IPO candidates to the sidelines, small issuers continue to list, dominating the IPO calendar in recent weeks. As we noted, ...read more